This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Lilly to Acquire Private Biotech for Boosting Pain Portfolio
by Zacks Equity Research
Lilly (LLY) inks a deal to acquire Disarm Therapeutics for an upfront payment of $135 million to strengthen its pain and neurological diseases portfolio.
Are You Looking for a High-Growth Dividend Stock? Eli Lilly (LLY) Could Be a Great Choice
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.
Pharma Stock Roundup: J&J's Q3 Earnings, Pause on Coronavirus Studies & Other Updates
by Kinjel Shah
J&J (JNJ) beats Q3 estimates for earnings and sales. J&J and Lilly (LLY) pause studies on their coronavirus vaccine and antibody candidates, respectively.
The Zacks Analyst Blog Highlights: JNJ, Eli Lilly, Merck, AbbVie and GSK
by Zacks Equity Research
The Zacks Analyst Blog Highlights: JNJ, Eli Lilly, Merck, AbbVie and GSK
FDA Accepts Biohaven's (BHVN) sNDA for Migraine Drug Nurtec
by Zacks Equity Research
Biohaven (BHVN) is seeking the label expansion of its migraine drug Nurtec ODT as a preventive treatment of migraine.
Pandemic Surges, Stimulus Fades: ETF Strategies to Follow
by Sweta Killa
Volatility has once again been playing foul in the stock market due to resurgent COVID-19 infections and fading hopes of additional stimulus. Investors should follow some techniques to minimize volatility in their portfolio.
Stocks Down 2nd Straight Day: Prime, Lilly, United Q3 & More
by Mark Vickery
Market indexes closed lower for their second-straight session, following a string of four days in a row higher.
Celldex Initiates Early-Stage Antibody Study for Skin Disorder
by Zacks Equity Research
Celldex (CLDX) is developing its monoclonal antibody candidate CDX-0159 as a potential treatment of chronic spontaneous urticaria.
Do J&J's Q3 Results Indicate a Sales Recovery for Big Pharma?
by Kinjel Shah
Investors typically look at J&J's (JNJ) results for signals regarding how the rest of the big drugmakers will fare.
Stock Market News for Oct 14, 2020
by Zacks Equity Research
Wall Street closed lower on Tuesday due to uncertainty on second round of coronavirus-aid package.
Lilly's Coronavirus Antibody Study Paused on Safety Concerns
by Zacks Equity Research
Lilly (LLY) is developing antibody candidates for a potential COVID-19 treatment in several clinical studies.
5 Must-Buy Blue Chip Stocks to Remain Safe in October
by Nalak Das
It will be prudent to invest in Dow stocks with a favorable Zacks Rank that are likely to provide solid returns in the near term.
Gilead & Galapagos Announce Positive Data on UC Candidate
by Zacks Equity Research
Gilead (GILD) and partner Galapagos report positive data on filgotinib for the indication of active ulcerative colitis.
Lilly's Mirikizumab Retains Efficacy in Crohn's Disease Study
by Zacks Equity Research
Eli Lilly's (LLY) mirikizumab continues to show symptom improvement and reduction of intestinal mucosal inflammation in Crohn's disease patients after a year-long treatment in a mid-stage study.
Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Eli Lilly (LLY) closed at $154.49, marking a -1.52% move from the previous day.
AstraZeneca's Coronavirus Antibody Therapy to Enter Late Stage
by Zacks Equity Research
AstraZeneca (AZN) plans to start two phase III studies in October for evaluating its cocktail antibody therapy for COVID-19. To this end, the company gets $486 million funding from the U.S. government.
The Zacks Analyst Blog Highlights: Mastercard, JPMorgan, Eli Lilly, Caterpillar and Anthem
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Mastercard, JPMorgan, Eli Lilly, Caterpillar and Anthem
Gilead Up on Positive Final Results for Coronavirus Treatment
by Zacks Equity Research
Gilead (GILD) gains on results from the phase III ACTT-1 study of investigational antiviral Veklury for the treatment of adults hospitalized with mild-moderate or severe COVID-19.
Pfizer's (PFE) Ibrance Fails in Early Breast Cancer Study
by Zacks Equity Research
Pfizer's (PFE) Ibrance is marketed for the treatment of HR+, HER2- advanced or metastatic breast cancer but not for any early breast cancer indication.
Pharma Stock Roundup: LLY, AZN, PFE, GSK Progress on Coronavirus Programs
by Kinjel Shah
Lilly (LLY), Pfizer (PFE) and AstraZeneca (AZN) provide updates on their coronavirus vaccine/treatment programs.
Regeneron Gains on EUA Request for Coronavirus Treatment
by Zacks Equity Research
Regeneron's (REGN) stock up following the submission of a request to the FDA for granting an Emergency Use Authorization to its experimental COVID-19 treatment, REGN-COV2.
Top Analyst Reports for Mastercard, JPMorgan & Eli Lilly
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Mastercard (MA), JPMorgan Chase (JPM) and Eli Lilly (LLY).
Company News for Oct 8, 2020
by Zacks Equity Research
Companies in the news are: LLY, SUNW, SOL, KIN
Lilly Seeks Emergency Use of Coronavirus Antibody Candidate
by Kinjel Shah
Lilly (LLY) applies to the FDA for Emergency Use Authorization of antibody therapy, LYCoV555. Releases promising data which shows that an antibody combination, LYCoV555 and LY-CoV016, is effective.
Best COVID Drug Stocks to Buy on Trump Recovery
by David Bartosiak
Two of the best COVID drug stocks to buy became evident following President Trump's speedy recovery.